Anke Biotech announced that AK2401 injection, a pabolizumab biosimilar drug independently developed by the company, recently obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and was approved to conduct clinical trials on solid tumors. This product is registered as a therapeutic biological product category 3.3: biosimilar.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.